<DOC>
	<DOC>NCT01579357</DOC>
	<brief_summary>The objective of this pharmacokinetic study is to exclude a possible influence of CETUX on the plasma disposition and metabolic activation of Capecitabine (CCB) and when this regimen is given combined with Oxaliplatin (OxPt).</brief_summary>
	<brief_title>Pharmacokinetics and Metabolic Activation of Capecitabine</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inclusion Criteria selected: signed written informed consent male or female &gt; 18 years Kras wild type adenocarcinoma of the colon or rectum metastatic colorectal carcinoma ECOG &lt;= 2 Exclusion Criteria selected: brain metastasis previous chemotherapy stage 3 or 4 heart failure uncontrolled angina pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>colorectal carcinoma</keyword>
	<keyword>K-ras wild type</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>exclude a possible influence of CETUX</keyword>
	<keyword>plasma disposition</keyword>
	<keyword>metabolic activation</keyword>
	<keyword>CCB</keyword>
	<keyword>OxPt</keyword>
</DOC>